Childhood Fibroblastic and Myofibroblastic Tumors: A Multicenter Documentation and Review of the Literature

Özgün Araştırma/Original article

Correspondence: Ayper KAÇAR
Department of Pathology, Ankara Children's Hematology and Oncology Research and Training Hospital, Ankara, TURKEY
E-mail: ayperkacar@yahoo.com Phone: +90 533 655 76 57

ABSTRACT

Objective: In this study, we aimed to give a documentation of 37 cases of childhood fibroblastic/myofibroblastic tumors retrieved from the archives of six reference centers in Ankara along with a comprehensive review on the subject.

Material and Method: A retrospective archive search was carried out for the period between 2006-2010 in 6 reference centers in Ankara covering patients with ages ranging between 0-18 years. All the tumors categorized under fibroblastic and myofibroblastic group according to World Health Organization criteria were collected.

Results: The study comprised 407 soft tissue tumors in total. Fibroblastic/myofibroblastic tumors constituted 9.1% (37 cases) of these tumors. According to histopathology; 16 cases were categorized as fibromatosis, 8 cases as inflammatory myofibroblastic tumor, 6 cases as infantile fibrous hamartoma, 3 cases as nodular fasciitis and 2 cases as infantile myofibroblastic tumor/myofibromatosis and 1 case as cranial fasciitis. The only malignant case was an infantile fibrosarcoma.

Conclusion: Infantile fibrosarcoma was lower than reported series and a male predominance was noted. The low incidence of newly described entities as well suggests that these tumors may have been unrecognized.

Key Words: Neoplasms, Fibrous tissue, Pediatric, Infant

INTRODUCTION

Fibrous tumors comprise 12% of all soft tissue tumors (STT) in the first two decades and 4% of all congenital tumors (1). Fibrous tumors have been found to be more frequent in infants under 1 years old, whereas above this age the neurogenic-myogenic tumors are more common. In this group of tumors, fibromatosi/myofibromatosis constitutes the majority of the cases (72%) followed by infantile fibrosarcoma (IFS) (13%) (1,2).
This study is based upon the documentation study of childhood solid tumors conducted by Ankara Pediatric Pathology Working Group in which detailed information about some epidemiologic characteristics of these tumors are provided (3).

In this study, we aimed to focus on fibroblastic/myofibroblastic tumors (FMT) excluding fibrohistiocytic tumors with variable biological behaviour like plexiform histiocytic tumor, angiomatoid fibrous histiocytoma and neurothekeoma. The results are discussed in the light of the published data paying special attention to some of the recently described and controversial entities. Classification tables according to age and biologic behaviour are also provided (Table I).

**Table I: Classification of fibroblastic/myofibroblastic tumors according to age and biologic behaviour**

<table>
<thead>
<tr>
<th>Fibrous tumors peculiar to infancy</th>
<th>Biological behaviour</th>
<th>Fibrous tumors of adult type</th>
<th>Biological behaviour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cranial fasciitis</td>
<td>Benign</td>
<td>Nodular fasciitis, proliferative fasciitis, ischaemic fasciitis, ossifying fasciitis; proliferative myositis, ossifying myositis; digital osteofibrous pseudotumor</td>
<td>Benign</td>
</tr>
<tr>
<td>Cardiac fibroma</td>
<td>Benign</td>
<td>Other fibromas (desmoplastic fibroma, nerve and tendon sheath fibroma)</td>
<td>Benign</td>
</tr>
<tr>
<td>Fibromatosis colli</td>
<td>Benign</td>
<td>Desmoid type fibromatosis (superficial and deep)</td>
<td>Intermediate (locally aggressive)</td>
</tr>
<tr>
<td>Fibrous hamartoma of infancy</td>
<td>Benign</td>
<td>Cellular fibrous histiocytoma</td>
<td>Benign</td>
</tr>
<tr>
<td>Calcifying fibrous tumor</td>
<td>Benign</td>
<td>Myxoma</td>
<td>Benign</td>
</tr>
<tr>
<td>Juvenile hyaline fibromatosis</td>
<td>Benign</td>
<td>Solitary fibrous tumor</td>
<td>Intermediate (rarely metastasizing)</td>
</tr>
<tr>
<td>Congenital and acquired muscular fibrosis</td>
<td>Benign</td>
<td>Dermatofibrosarcoma protuberans</td>
<td>Intermediate (rarely metastasizing)</td>
</tr>
<tr>
<td>Infantile fibromatosis</td>
<td>Intermediate (locally aggressive)</td>
<td>Angiomatoid fibrous histiocytoma</td>
<td>Intermediate (rarely metastasizing)</td>
</tr>
<tr>
<td>Infantile fibrosarcoma</td>
<td>Intermediate (rarely metastasizing)</td>
<td>Adult type fibrosarcoma</td>
<td>Malignant</td>
</tr>
<tr>
<td>Giant cell fibroblastoma</td>
<td>Intermediate (locally aggressive)</td>
<td>Low grade fibromyxoid sarcoma</td>
<td>Malignant</td>
</tr>
<tr>
<td>Gardner associated fibroma</td>
<td>Benign</td>
<td>Sclerosing epitheloid fibrosarcoma</td>
<td>Malignant</td>
</tr>
<tr>
<td>Infantile myofibromatosis</td>
<td>Benign</td>
<td>Low grade myofibroblastic sarcoma</td>
<td>Intermediate (rarely metastasizing)</td>
</tr>
<tr>
<td>Infantile digital fibromatosis</td>
<td>Benign</td>
<td>Synovial sarcoma</td>
<td>Malignant</td>
</tr>
<tr>
<td>Calcifying aponeurotic fibromatosis</td>
<td>Benign</td>
<td>Rhabdomyofibrosarcoma</td>
<td>Malignant</td>
</tr>
<tr>
<td>Juvenile nasopharyngeal angiofibroma</td>
<td>Intermediate (locally aggressive)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebriform fibrous proliferation (proteus syndrome)</td>
<td>Benign</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingival hereditary fibromatosis</td>
<td>Benign</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipofibromatosis</td>
<td>Intermediate (locally aggressive)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory myofibroblastic tumor</td>
<td>Intermediate (rarely metastasizing)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plexiform fibrohistiocytic tumor</td>
<td>Intermediate (rarely metastasizing)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MATERIAL and METHODS

A retrospective archive search was carried out for the period between 2006-2010 in 6 reference centers in Ankara* covering patients with ages ranging between 0-18 years. Histopathologic diagnoses were checked case by case and all the tumors under fibroblastic and myofibroblastic group were collected in order to analyze these tumors by using parameters of age, sex, localization, histopathologic diagnosis and biologic behavior. The age groups were formed as 0-1 years, 1-4 years, 4-10 years, and 10-18 years. Classifications for diagnosis and tumor behaviour were established according to World Health Organization (WHO) criteria.

RESULTS

The study comprised 407 STTs in total. The breakdown of the cases with respect to the age groups was as follows: 0-1 years: 44; 1-4 years: 79; 4-10 years: 119; 10-18 years: 164 cases. Distribution of the whole STT cases according to histopathology is provided in Table II. FMT constitute 9.1% (37 cases) of these tumors. There were 31 males (83%) and 6 females (17%) in this group. The data on age was available for all patients. There were 9 FMT (20.5%) in 0-1 years group. There was no newborn case in this group, with the youngest patient being 2 months old. The number of FMT cases in the other age groups were as follows: 1-4 years: 7 cases (8.9%), 4-10 years: 10 cases (8.4%), 10-18 years: 10 cases (6.1%).

According to histopathology; 16 cases were categorized as fibromatosis (2 fibromatosis coli, 1 superficial and 13 deep fibromatosis). There were 4 females and 12 males, age ranges from 2 months to 17 years (median age 8 years). The localizations of the tumors were as follows: 3 upper extremity, 3 lower extremity, 3 thoracic wall, 3 glutea, 2 neck, 1 frontal region, 1 mandible (Figure 1A, B).

There were 8 cases diagnosed as inflammatory myofibroblastic tumor (IMT) histopathologically (Figure 2A-C). All but one case was male. The age of the patients ranged between 2-12 years (median age 7.2 years). The localizations were as follows: 2 intestine, 1 rectum, 1 thoracic wall, 1 lung, 1 pelvic soft tissue, 1 cranium.

Six cases were diagnosed as infantile fibrous hamartoma (IFH) (Figure 3). All the cases were male with age ranging between 5-17 months (median age 1 year). Two cases were...

*Hacettepe University, Pediatric Pathology Unit; Pathology Department of Gazi University, Pathology Department of Ankara University, Dr. Sami Ulus Child Diseases Research and Training Hospital, Dışkapı Yıldırım Beyazıt Research and Training Hospital, and Ankara Child Diseases, Hematology and Oncology Hospital.
localized in the axilla, 1 in the neck, 1 in the thoracic wall, 1 in the sacral region and 1 in the scrotum.

There were 3 nodular fasciitis (NF) cases, all males with ages ranging between 5-13 years (median age 10 years). Two cases were localized in the cranium and upper extremity while the localization was unknown for 1 case.

Two cases were diagnosed as infantile myofibroblastic tumor/myofibromatosis (a 1-year-old male and an 18-year-old female). The tumors were localized in the liver and lower extremity.

The single cranial fasciitis (CF) case was 1 year old male with orbit localization.

The single malignant case of our series was a 4-month-old male IFS case who had presented with an upper extremity localized mass (Figure 4).

**Figure 2:** A) White-cream solid mass. Note that the mass lack the fasciculated cut surface, B) IMT showing cellular pattern, composed of spindle cells with voluminous nuclei intermingled with inflammatory cells and ganglion like cells, C) IMT with a sclerotic pattern in the thigh of a ten year-old girl.

**Figure 3:** IFH in the axillary region of an 18 month-old male. Note the intermingling of primitive myxoid tissue, collagenous spindle cell areas and the fat.

**Figure 4:** Densely cellular neoplasm of intersecting fascicles of scattered ovoid and spindle cells.
**DISCUSSION**

Childhood FMT can be classified according to histology, age and biologic behavior (Table I). Fibrous tumors that are peculiar to infancy are listed in Table I, and in general have no clinical or morphological counterpart in adult life and pose a special problem in diagnosis because of their rarity. Their unusual microscopic features fail to accurately reflect their biological behavior and may be mistaken for evidence of malignancy and cause unnecessary and excess therapy (4). Adult type FMT are listed separately and are rarely seen in this population. Most of the pediatric FMT fall into the benign category. There are limited series concerning these tumors in the literature (1). Although this study was designed to document these tumors in the Ankara region, taking into account that the contributing centers to this study are among the biggest referral centers in the country, the study can be assumed to represent wider data about Turkey. Our data showed that FMT comprise 9.1% of all childhood STTs. The incidence was higher in infants (0-1 years) with 20.5% of STTs for this age and descended slowly with the increasing age. Although myofibromas constitute significantly a smaller part of this group with only two cases, in accordance with the literature, the fibromatosis/myofibromatosis group constituted the majority of our cases in this group (43.2%), followed by IMT (21.6%), IFH (16.2%) and NF (8.1%) respectively. We had a single case of CF (2.7%) and a single malignant case of IFS (2.7%). The incidence of IFS in our study was low compared to the published data (2). According to gender, 31 of 37 children were male (83.8%) which was a striking finding in the present study. In the series of Dr. Coffin, the ratio for male/female was 1.8/1 and the median age was 7 years (2). While the median age was almost compatible with the literature (5.2 years) in our series, the male predominance (m/f=4.8/1) was significant. The biggest FMT series in the literature comprised 103 patients, and the male/female ratio in this study was 1.8/1 (2). Although this result already indicates a certain male tendency, this data is not verified with further series in the literature. Making a comparison regarding this bias is not straightforward since this group of tumors is not documented widely in the literature. On the other hand, our results showed a distinctive predominance of male gender in our series. In our opinion, this data should be verified by further documentations in the literature.

We also note that some fibroblastic entities peculiar to childhood such as Gardner-associated fibromas, inclusion body fibromatosis, juvenile hyaline fibromatosis and newer entities like lipofibromatosis were consistently lacking in our series. Some other entities such as IFS (1 case) and CF (1 case) had lower incidences when compared to the published data, while NF was much more common (3 cases). This led us to consider that childhood FMT could have been unrecognized and diagnostic experience related to these tumors might be still lacking. In our opinion these data should be reevaluated in larger series with a central review carried by the experts in the field.

Cranial fasciitis is the only reactive fibroblastic lesion that is peculiar to infancy. Other types of fasciitis are uncommon in children. It is similar morphologically and histologically to its adult counterpart NF, except for its occurrence in infants under 2 years old. It is typically well circumscribed and the histology is similar to NF with variably myxoid and hyalinized matrix occasionally with foci of osseous metaplasia. Nodular fasciitis is rare in children. Both CF and NF are completely benign, probably reactive lesions cured with local excision. Intravascular fasciitis is a rare form of NF with a young age predilection. It has a benign course with rare recurrence (5). Proliferative fasciitis (PF) and myositis are principally lesions of adults. A rare variant of PF is described in children (6).

Gardner-associated fibroma and cardiac fibroma are the most frequent types of fibroma encountered in childhood. Clinically they are defined as solitary or multiple superficial and soft tissue fibromas associated with Gardner’s syndrome (70-90% of cases) and desmoid fibromatosis (18-45% of cases) with a predilection for childhood and adolescence that is caused by the mutation of the APC gene on chromosome 5 (4,7,8).

**Table III:** Cellular infantile fibromatosis: differential diagnosis with infantile fibrosarcoma

<table>
<thead>
<tr>
<th>Features</th>
<th>Infantile Fibromatosis</th>
<th>Infantile Fibrosarcoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellularity</td>
<td>variable</td>
<td>moderate to high</td>
</tr>
<tr>
<td>Herringbone pattern</td>
<td>absent</td>
<td>usually present</td>
</tr>
<tr>
<td>Mitotic figures</td>
<td>rare</td>
<td>few to many</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>absent</td>
<td>often present</td>
</tr>
<tr>
<td>Necrosis</td>
<td>absent</td>
<td>often present</td>
</tr>
<tr>
<td>t(12;15)(p13;q25)*</td>
<td>absent</td>
<td>present</td>
</tr>
</tbody>
</table>

*see reference (18).
Infantile myofibromatosis is the most common fibrous disorder of infancy and childhood. Principally it is a tumor of infancy as most of the cases are detected at birth or under 2 years. There are familial cases reported in the literature (9). Clinico-pathologic similarities between infantile hemangiopericytoma (HPC) and infantile myofibromatosis have suggested that both lesions might belong to the same spectrum of disease and probably are of a pericytic nature (10). Today it is widely accepted that infantile HPC represents the immature form of infantile myofibroblastic tumor, and is hence considered an infantile form of myofibromatosis (11). The prognosis is excellent. Congenital cases with visceral involvement have a poor prognosis and the mortality is about 75%. Rare spontaneous regression is reported (12).

Juvenile fibromatosis is a designation that has been applied to a morphologically diverse group of locally aggressive STTs. This type of infantile fibromatosis probably represents the same spectrum of disease with the recently described lipofibromatosis (4,13). Superficial forms of adult type fibromatosis are extremely rare in childhood. Infantile fibromatosis (IFM) is no longer retained in the new WHO classification system as a term; instead, lipofibromatosis is present in the classification to cover this tumor group. Thus, lipofibromatosis is a recently-described entity comprising part of the spectrum of old infantile fibromatosis terminology (13). It typically originates in the skeletal muscle as an ill-defined, slowly growing, solitary mass. It consists of mature adipose tissue as an integral component and intersecting trabeculae comprising a spindle cell component. Fat typically makes up more than 50% of the specimen (13). The key proliferative element is the fibroblastic component and non-destructive recurrence is frequent when incompletely excised. Occasional non-recurrent cases are reported, despite the positive surgical margins (14). This phenomenon is attributed to lesional maturation analogous to that described in other benign fibrous and lipomatous tumors (13).

Fibrosarcoma in newborns, infants and small children bears some resemblance to adult fibrosarcoma, but it must be considered as a separate entity because of its markedly different clinical behaviour as well as its distinctive molecular alterations. IFS constitutes 12% of soft tissue malignancies in children and is morphologically and genetically related to congenital mesoblastic nephroma (15). It presents as a rapidly growing mass of large size that arises in the deep tissues of extremities (70%), followed by the trunk and head and neck (16). Histologically, it is an infiltrative, densely cellular neoplasm of intersecting fascicles of primitive ovoid and spindle cells with a herringbone pattern. Increased mitosis, little pleomorphism, variable collagen and scattered chronic inflammatory cells are common. Necrosis, hemorrhage, dystrophic calcification, extramedullary hematopoiesis may be encountered. The diagnostic features are the uniformity of the cells, the solid growth pattern and fascicular arrangement with a lymphocytic infiltrate, and the absence of specific differentiation indicative of other tumor types. There are reports about existence of composite tumors with features of myofibromatosis, infantile HPC and IFS and a histogenetic relationship between these entities is suggested (17). A cellular form of desmoid type fibromatosis may pose a problem in the differential diagnosis. Table 3 shows some useful criteria for the distinction of these tumors (18). Tumors can start with the appearance of one and recur as the other (19,20). There is compelling evidence that some cases of IFM carry some similar cytogenetic changes with IFS (21,22).

IMT is a fibroblastic tumor occurring principally in the viscera and soft tissues of children and young adults with a mean age of 10 years that has an intermediate biologic potential but which usually follows a benign clinical course. Today IMT is accepted as a distinct entity with clinical, pathological and molecular characteristics (23). Many have been associated with aggressive local or distant behaviour that has resulted in some deaths (4,24). In addition, some tumors show aberrations of the ALK-1 gene supportive of a neoplastic process (25-28). In children differential diagnosis should be done basically with embryonal rhabdomyosarcoma (RMS), CF, extrapulmonary solitary fibrous tumor, solitary myofibroma and fibromatosis. Histopathology is essentially non-predictive in reflecting biologic behavior. Spontaneous regression has been reported in some cases.

Childhood fibroblastic and myofibroblastic tumors comprise an evolving area with many overlapping features. Pediatric fibroblastic tumors generally have a better overall prognosis than their adult counterparts. The critical differential diagnoses not to be missed can be summarized as follows: proliferative fasciitis vs RMS; ossifying fasciitis/myositis/periositis vs osteosarcoma; IFS vs synovial sarcoma, spindle cell RMS, rhabdomyofibrosarcoma and malignant peripheral nerve sheath tumor. A useful immunohistochemical panel for these tumors might include CD34, ALK, actin, desmin, β-catenin, h-caldesmon, calponin, S100, factor XIIa and CD68.

It should be taken into account that histology alone is not predictive and immunohistochemical and cytogenetics do not aid too much in the differential diagnosis of these tumors. An accurate diagnosis can be achieved by appropriate evaluation of clinical presentation, localization, age and morphology together.
In conclusion, our findings were similar to the original observations made by Dr. Coffin and his colleagues (2), with the exceptions of higher male incidence along with a lower incidence in myofibroma and IFS cases.

ACKNOWLEDGEMENT

We would like to express our sincere thanks to Prof Dr. Sergül Dervişoğlu and Prof. Dr. Erdener Özer for their valuable review on the manuscript.

REFERENCES